Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 6-Week program ease long COVID? new study tests Day-Hospital care

NCT ID NCT05532904

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 6-week personalized day-hospital program could improve quality of life for 80 people with persistent long COVID symptoms like fatigue, shortness of breath, and brain fog. The program included group education, tailored exercise, and cognitive behavioral therapy. Researchers compared this to usual care (a waiting list) to see if the structured approach made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized multidisciplinary day-hospital program (education, exercise, cognitive behavioral therapy)
What this could lead to
If it works, this could point toward an effective structured program to improve quality of life for people with persistent long COVID symptoms.
What could go wrong
This is a small, completed trial with only 80 participants, so results may not apply to everyone. The program is intensive and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jan 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having had an initial episode of symptomatic COVID-19 according to one of the following criteria: * SARS-Cov-2 PCR + * SARS-Cov-2 + antigenic test * SARS-Cov-2 + serology * Prolonged anosmia/ageusia of sudden onset * Typical chest CT scan * Still having at least one of the initial symptoms and possibly new symptoms including fatigue, dyspnea, cognitive impairment or pain beyond 4 weeks after the onset of the acute phase of the disease. * These initial and persistent symptoms are not better explained by another diagnosis not known to be related to Covid-19. * These symptoms are the cause of an alteration in quality of life and global functioning deemed significant by the patient. * Having an indication to either supervised exercise and / or cognitive behavior therapy and / or cognitive remediation Exclusion Criteria * Medical emergency requiring management not compatible with research * Neuropsychiatric disorder likely to alter cognitive functions, prior to the Covid-19 episode * Medical contraindication to exercise training such as pericarditis or progressive myocarditis * Patient under state medical assistance * Patient who does not speak French * Pregnancy in progress

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-COVID-19 condition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Motor Activity post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-COVID-19 condition

Contacts and locations

Locations

  • Hôtel Dieu Hospital

    Paris, 75004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.